Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the Affordable Care Act (aka Obamacare), the pharmaceutical industry is still growing at a healthy clip, thanks primarily to the introduction of several game-changing new therapies for cancer and rare diseases over the past few years.
Within the realm of Big Pharma, for instance, AstraZeneca (NYSE:AZN), Pfizer (NYSE:PFE), and Sanofi (NYSE:SNY) all offer juicy dividend yields that exceed 3% at the moment, as well as broadly positive outlooks from both a near -- and long-term perspective. Armed with this insight, let's consider why these three pharmaceutical giants may be worth owning in 2018, and beyond.
Source: Motley Fool
Related Articles:
- 7 Stocks With A Vision Of Higher Dividends
- 6 Higher-Yielding Consumer Stocks With A History of Rising Dividends
- Are Defense Stocks Good Defensive Stocks?
- 10 Stocks That Have Paid Uninterrupted Dividends Since 1895
- Who is David Dodd and Why Should We Listen to Him
________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.